<DOC>
	<DOCNO>NCT01856595</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics multiple ascend dos PF-06291874 Type 2 Diabetes patient .</brief_summary>
	<brief_title>PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males female subject nonchildbearing potential age 18 70 year , inclusive age time screen visit . Female subject nonchildbearing potential must meet least one follow criterion : 1 . Achieved postmenopausal status , define : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum FSH level within laboratory 's reference range postmenopausal female ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . 4 . All female subject ( include female tubal ligation females NOT documented hysterectomy , bilateral oophorectomy and/or ovarian failure ) consider childbearing potential . Body Mass Index ( BMI ) 18.0 45.0 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . PART A ONLY : Subjects treat metformin monotherapy least 3 month time screen visit ; stable dose metformin least 6 week prior first dose study drug Day 1 . Subjects must take minimum total metformin daily dose least 1000 mg . Subjects treat dipeptidyl peptidase4 inhibitor ( DPP4i ) , sulfonylurea sodiumglucose cotransporter2 inhibitor ( SGLT2i ) combination metformin may eligible washed DPP4i , sulfonylurea SGLT2i minimum 4 week prior dose . Subjects wash DPP4i , sulfonylurea SGLT2i still need meet fast glucose requirement define Inclusion Criteria . PART B ONLY : Subjects treat metformin plus sulfonylurea least 3 month time screen visit ; stable dose metformin sulfonylurea least 6 week prior first dose study drug Day 1 . Subjects must take minimum total metformin daily dose least 1000 mg total daily dose sulfonylurea least minimum recommend start dose find product label . Subjects treat DPP4i SGLT2i combination metformin sulfonylurea may eligible washed DPP4i SGLT2i minimum 4 week dose . History Type 1 diabetes mellitus secondary form diabetes . One selfreported hypoglycemic episode severe intensity within 3 month screen ; two selfreported hypoglycemic episode severe intensity within last 6 month . Recent [ ie , within six ( 6 ) month prior screen ] evidence medical history unstable concurrent disease : clinically significant hematological , endocrine , pulmonary , gastrointestinal ( include severe gastroparesis ) , cardiovascular , hepatic , psychiatric , neurologic , clinically significant allergic disease ( exclude treat untreated seasonal allergy time dose ) . Subjects chronic condition T2DM ( example , hypercholesterolemia hypertension ) control either diet stable ( last 4 week prior screen ) dos medication may include well ( example , subject hypercholesterolemia appropriate treatment eligible ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>